Thanks, right. Steve. All
I'll now with R&D our give on an programs, beginning update XXXX. you
So the as drug in CohBar's it's testing mitochondria-based candidate Ia/Ib of It's resumed in for is NASH study a of clinical currently and a adults. multiple-ascending lead assessment pharmacokinetics currently ongoing. of safety, treatment is healthy part dose, and obesity. Phase potential Phase in as a Phase June CBXXXX, therapeutic. The CBXXXX Ia conventional Ia/Ib reminder, dose, and is tolerability The single-ascending a the study
on nonalcoholic disease, designed a effects Ib liver CBXXXX to study is biomarkers weight the this expected with currently the quarter the on relevant and or potential meet gave in various that assess of Phase are time part activity somewhere disease. on Following track to second NAFLD, obesity to The line we metabolic the third last fat, of of NASH, call in that line top study body data the obese liver subjects expected with is fatty XXXX. and readout
next obese to start study blinded the we the the the is expect as assessments Phase treatment, still in planned, and progress If be goes on to of and We're updates provide study when to milestone as the study we subjects. expected significant such Ib NAFLD the milestones.
investor on the We progress next on our will call. update you
release the of cells. obesity. involving mechanism CBXXXX regulation opportunity it's which fat acid of mechanisms. that shared animal other with has for mechanism and that with data previously action, preclinical NASH CBXXXX, drugs for in a fatty of from models novel presents demonstrated both combination novel efficacy an And We've different of CBXXXX
type agonist. and synergy shared data of with CBXXXX showing also are PPAR-gamma diabetes X more that drugs patients of GLP-X to interestingly, diabetic. of We treat than These NASH used with are and two classes previously are XX% commonly
please. slide, Next
pipeline that expanded assessment have efforts additional Now of main mitochondria-based and therapeutic identifying and on let's of broadening X We've significant call. towards talk their progress and about candidates of areas, the rest our we our potential. shared last progress therapeutic some in research made our CohBar's
The new also show lung in first fibrotic decreased with a in promising we've diseases fibrosis. activity a some cover from fibrosis the decrease mouse our study that'll biomarkers some data model from I'll in I'll of shown is of of inflammation. peptide idiopathic share you cultured today where human that novel fibrosis decreased anti-fibrotic pulmonary analogues cells and corresponding area in setting
cancer, area novel identified and is vitro, second immuno-oncology analogues of ability of to what human the is enhance where we've cells blood an that in as peptide The progress kill cancer in referred to cells model.
beneficial of surface third recently and of setting the of new our American shared family a called at interaction including in peptides details cell diabetes. where meeting important Diabetes The the June, of apelin glucose models receptor. novel Association of peptides of on progress receptor regulation discovery these peptides family between effects the in key this type area in research, is with identified We diabetes of X a we animal
Next slide, please.
significant anti-fibrotic with peptides start So in identifying potential. let's made We've new progress fibrotic diseases. with
to the and including fibrosis but Now fibrosis lung, also process tissues disease-related the tissue kidney is response a injury, of age-related underlines liver, diseases. age progression scaring and heart, of like in other NASH and normal
you a key inflammation pulmonary #X, MBT in fibrosis significant CohBar's the fibrosis. showed biomarkers previously of peptide a We in produced decrease cell-based and of model
#X of Now data vivo for fibrosis. lung the well-established again, mouse see, in slide, in on you of MBT model some this a
then vehicle treated compared In the with were very induce for response control fibrosis. human not were then to bleomycin receive to that's mice idiopathic to normal this CohBar weeks pulmonary animals peptide did study, bleomycin. similar or disease, dosed a and with a Animals that X
After lung and Ashcroft changes scale by using was called scale. tissue were scored XX the lungs days, the the objective microscopy examined an
on changes. Now fibrotic the the lung extent Ashcroft the fibrosis grades based damage score of and
on scale. on that about left, controlled are vehicle a animals in significant with the the So X figure XX of you see reaching that fibrosis, level top treated days, the Ashcroft had can at
While fibrosis those score. lower significantly peptide Ashcroft daily treated once CohBar had with a
visually the lungs also of you bottom photo in slide. micrographs can effect at of see Now that the the the
There you not see far a normal In left that middle, see damage formation is receive of marked here days. followed by treatment which after the red appearance significant some fiber So with days the bleomycin of induction are on fibrotic XX thickening animal effect the many arrows. there, the XX lung did lungs of with bleomycin with the notes, vehicle you the of issue and of control.
for peptide, there's clear protection, animals and bleomycin with treated CohBar days anti-fibrotic then indicating in However, XX to activity. exposed
model. data in show disease efficacy efficacy preliminary a These into in-vitro a translation the of signal direct
our and conducting other we're confirmatory we heart and models of of animal chronic will kidney studies, failure. fibrotic diseases, expanding be including to now evaluation So models disease
Next slide, please.
based treatment in days new using In lung a shows bronchoalveolar study XX Now after inflammation this cells the are we the data fibrosis model. at lung slide number the on mouse of in lung looking same case, from inflammatory some lavage. of this
present with that treated there at no For are fluid been bleomycin, not XX lavage have normal mice the lymphocytes days. in
induced are bleomycin in with the days, mice You see induced is inflammation are and the of fluid. the with in blue lymphocytes that for the XX% lavage XX now dots. When and cells vehicle present control treated for account the that
induced lower As numbers lymphocytes see in with cells. now fluid, MBT show can bleomycin, X in the the presence inflammation. green, XX% the Based of mice with our less a on of but new you very reduction lavage than representing the significant peptide, of in treated
#X diseases. in So additional for of range CohBar's fibrotic suggests data and is potential the a treatments as still opportunities inflammatory preliminary of MBT peptides process optimization, for these but
please. slide, Next
been or immunotherapy boost enormous invading So cancer In to this blood using our enhance at approaches cells to as immuno-oncology. of cancer Recently, immune known approach area advances our novel cells have in cancer. looking own in to ability efforts cure of one using now our of they we're we'll CohBar's that own cancer this until turn ability of recognize treatment peptides the cells. the to a the slide, field cells,
the activated grown together a called will cells immune see peripheral cells data mononuclear then cell attack blood SK-Mel-XX. model stimulated this tumor we human Biosciences. PBMCs in from are our or partner, called external immuno-oncology run response. was blood This line. line this human preliminary cells. In cancer then cells in study, standard Now PBMCs that to CRO slide, is The are cell vitro by PhenoVista The an an melanoma human with blood induce
and When reflected in peptides, cancer stains of measure enhancement can immune we response their We our stimulated more for incubate those on imaging of presence potential we number of that special effect look death. cancer as same techniques. by cells remain in the cell the microscopy the any live cells using
of case, we increase in the significant specific a this MBT cells in highly of the So presence killing cancer saw #X. in
the On which cells the is or designed is represented hours see images XX all the you cells, cancer specifically using to stains left, of just the green. cells, show the the which blue,
the forward in we'll are, These immunotherapy. You and peptide models see a substantial course, can early moving decrease and present. into was are animal cancer be data, now with additional surviving there expanding was we cells clearly cancer studies when the of of
Next slide, please.
our CohBar's meeting summary the So the is some we Association This the have previously evaluation Francisco. area treatments the shared sessions diabetes. annual data Diabetes in third X as potential at progress of type is of of novel a San American for of slide peptides scientific brief and XXth recent of presented the
or a a the mitochondrial-encoded analogues X novel We effects CohBar. family discovery peptides a to which mice, human family reported of discovered This is of DIO in of peptide, peptide CBXXXX, has new related diabetes. diet-induced obese by of model beneficial type
loss fat of for produced on the once XX the significant to weight days vehicle-treated and see mass animals. body a can analogue daily you left a As dosed slide, CBXXXX compared with loss
in glucose left, plot model. this bottom the in in the also shown as tolerance peptides addition, improved these In
discovery poster peptides the one selective the interaction with these presented Now a ADA specific also apelin of of receptor, very receptor. our
many and to a it is processes. lung, appears regulating liver tissue, apelin expressed metabolism, key peptide cardiovascular function, a fluid receptor has and function The number play a and brain. tissues, the other homeostasis by natural energy kidney, heart, Apelin of adipose in role others, cellular in including apelin of and explored been the different
peptide the the on As similar CBXXXX that bottom able black of response that the we to a occurring apelin receptor, effect naturally some the can show of figure blue novel the the our bar. shown apelin, produce the at peptide in bars, were maximum analogues to is maximum right,
peptides in Now these novel also potential the type family door diabetes, settings. utility but results disease of of open in metabolic to X this other
Next slide, please.
slide and obesity expanding optimization our where NASH an us CBXXXX, for indications mitochondria-based last new potential programs overview are first list in this that candidate, analogues clinical a Phase for R&D process. testing and current in therapeutics. of clinical discovery brings I So back to currently MBT behind high-level of our the
type cancer. with new X the research These these our include goal continuing like identifying potential we're diseases apply to areas additional MBT candidates. And of to drug and diabetes, expanded resources ultimate fibrotic areas of
to hand that, And back with Steve. I'll it
